This Under-The Radar Stock Is At The Vanguard Of A Huge Emerging Sector...

By Mark Sheridan



MINDCURE –Leading A Healthcare Revolution With Big Data Tech And Ground-Breaking Research

The world is suffering from a mental health crisis.

It’s only been accentuated by the rise of coronavirus and further isolation over the past year.

Close to a billion people worldwide are now living with a mental illness in one form or another.

And the worst thing is…

Many of these individuals do not have access to adequate treatment.

Today’s antidepressants and psychotherapies are not working for 30% of patients, leaving hundreds of millions struggling around the globe.

But today, a new avenue of treatment is opening up – and it’s one that might take you by surprise.

Over the past few years, we have seen a huge rise in the amount of research being conducted into the therapeutic qualities of psychedelic compounds.

Whether its psychological disorders like anxiety, PTSD, or depression…

Or physiological issues like pain, migraines, cluster headaches, and traumatic brain injury…

Scientists and researchers are repeatedly finding that chemicals like psilocybin (the active ingredient in magic mushrooms), ketamine, and ibogaine represent extremely effective treatment solutions.

Unlike many products currently in the market, psychedelics address the underlying causes of mental disorders rather than the symptoms alone.

This is why, after decades of being outlawed, the substances are becoming increasingly talked about and moving into the mainstream.

It’s why globally-influential regulators like the FDA are giving more and more allowances to researchers, accelerating their investigations into psychedelic-assisted therapies for a variety of disorders.

And it’s why under-the-radar biotech company MINDCURE could be an exciting investment opportunity.

iSTRYM™ – A Revolutionary Therapeutic Tool For Patients And Clinicians

A key focus for this Canadian firm is improving the quality of psychedelic-assisted therapy.

As it stands, the model is flawed.

The monitoring of patients enrolled into courses of treatment is limited largely to periodic therapy sessions with clinicians. This leaves long periods in-between, when they are not being supported or providing critical feedback on their progress that could lead to ground-breaking insights.

Meanwhile, the large majority of psychedelic therapy that is being carried out globally typically exists in cloistered scientific communities. It’s out of the hands of therapists where it could be used to help treat patients.

MINDCURE believes that filling in these data collection gaps is essential to advancing the world of psychedelic-assisted therapy. 

That is why it has developed iSTRYM™.

iSTRYM™ is a proprietary, centralized management for therapeutic insights that can be used by clinicians, patients, and researchers alike.

It has an app component, enabling patients to record real-time data like their heart rate and location as well as journal entries on how they are responding to psychedelic-assisted treatments on a day-to-day basis.

But it also brings together the large database of protocols, insights, and procedures arising from psychedelic research carried out on patients and in labs worldwide.

The result?

A digital information warehouse that is continuously aggregated to provide potentially transformational insights into the therapeutic qualities of psychedelic compounds using AI and strategic data loops.

Everyone benefits:

  • Therapists are given the data and conclusions needed to provide highly personalized, long-tail support to their patients, ultimately increasing positive outcomes and clinic revenues.

  • Patients are not only turned into informed and autonomous participants in their own mental wellness journey, but they are also supported by AI that works to understand and support them outside of the clinic.

  • Researchers are given a tool to deliver faster results using cleaner data and richer insights.

iSTRYM™ is a big data play that could not only help millions around the world.

It also represents a unique near-term revenue opportunity in a sector where long-term gains could be some way off due to regulation.

Given the rapidly growing research into psychedelic medicine, the commercial opportunity on offer here for MINDCURE is vast.

There is also another way the platform benefits the firm.

You see, as well as developing revolutionary proprietary technology…

MINDCURE is carrying out psychedelic research programmes to create its own patentable combination therapies and new molecular compounds.

To do this, the firm has created a second proprietary big data platform called PsyCollage™.

This aggregates historical psychedelic drug research and identifies the disorders where psychedelic compounds have been most effective as treatments as quickly as possible.

The organization has also assembled a team of scientists and psychedelic influences with unparalleled expertise when it comes to formulating novel psychedelic compounds and unique combination therapies.

Now, thanks to iSTRYM™, the company has the critical tool it needs to build on this stellar head start and advance its product research programmes as quickly as possible.

MINDCURE has completed a commercial agreement with ATMA Journey Centers, the first organization to provide psychedelic-assisted therapy to a Canadian patient.

Together, the pair will roll iSTRYM™ out across ATMA’s clinics both in Canada – where it is based – and internationally.

The deal will support ATMA’s therapists and patients, with access to iSTRYM™ providing the very best psychedelic-assisted therapeutic experience and outcomes possible.

But it will also enable ATMA to participate in MINDCURE’s research programmes – specifically focusing on priority indications like pain, neuroregeneration, migraines, and cluster headaches.

The patient data and insights iSTRYM™ gathers and creates will be invaluable to MINDCURE’s research team.

The deal is another excellent way for the firm to push forward in the long-term race to create patentable psychedelic products that will eventually reach the market.

And when it comes to the potential value these products could create, the outlook is very exciting.

According to Data Bridge Market Research, the psychedelics market is expected to grow 16.3% annually and be worth a staggering $6.85 billion by 2027.

It’s no wonder many of MINDCURE’s peers are now developing their own ‘digital therapeutics’ platforms like iSTRYM™ to accelerate product rollout.

Examples of other digital therapeutics platforms in the psychedelic space like iSTRYM™


Primed For Growth As Interest In Psychedelic Stocks Grows


With so much potential cash to be made… 

It won’t be surprising to hear that psychedelic medicine and research companies are now attracting major financial backing.

Billionaires like Peter Thiel – co-founder of PayPal and the first outside investor in Facebook – and Mike Novogratz are getting involved. 

So is Steve Cohen, the owner of the New York Mets, and Bob Parsons, the founder of GoDaddy.

More and more smart money is rolling in, and the growing group of psychedelic stocks listing on public markets have now collectively raised more than US$500 million in financing.

But over the coming months, this figure stands to increase considerably.

The potential catalyst is ATAI Life Sciences, a global biotech company operating in the realm of psychedelic mental illness solutions.

The firm is slated to go public in March of April with an IPO valuation of between US$1 billion and US$2 billion.

The last time the psychedelic sector saw an IPO anywhere close to this value was Compass Pathways in September 2020.

When it did, it pushed the psychedelic market further into the spotlight – and, in turn, into the radars of many more retail investors.

The value of almost every associated stock sharply increased in a matter of days.

Compass Pathways’ IPO market cap came in at $544 million…

So, if ATAI can hit the market with a valuation in the forecast range, one can only imagine the inflows it could bring to the wider psychedelic sector.

MINDCURE would be among the stocks positioned to benefit the most.

Aside from the obvious commercial potential of its business model, there’s the fact it recently listed on the first-ever exchange-traded fund, or ETF.

This not only marks it out as a quality stock, but it also opens it up to inflows from new investors looking to get wide exposure to the psychedelic stocks instead of picking specific names.

There’s also the fact the company is trading at a significant discount to many of its peers.

In fact, it is so under-the-radar at the moment that its current market cap barely surpasses its healthy C$26.6 million cash balance.

Bottom line is, MINDCURE is at the vanguard of the psychedelic sector, leading the race for patented products and developing patented technology to revolutionize treatment.

But this upside is currently being heavily overlooked by the market.

The company is something of an undiscovered gem as it stands, but the way things are going this is unlikely to be the case for long.

Investors who don’t move now risk missing out on a potential opportunity to generate strong profits from a firm driving the fight to help millions around the world.




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by MINDCURE’s agency of record, SandStone Media to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and sixty-six thousand US dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.


Author: Mark Sheridan

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Mark Sheridan does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Mark Sheridan has not been paid to produce this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter